Table 2.
Data are shown as median (interquartile range); Significant between group P-values are shown in bold.
| A. Change in Markers of Immune Activation and Arterial Inflammation at Week 12 (mITT population) | ||||||
|---|---|---|---|---|---|---|
| Change in Pitavastatin | Change in Pravastatin | P-value* | Percent Change in Pitavastatin | Percent Change in Pravastatin | P-value* | |
| sCD163 (ng/mL) | −26.1 (−122.8, 130.8) N=112 |
−21.1 (−139.8, 110.3) N=116 |
0.88 | −3.8 (−14.5, 11.9) N=112 |
−2.1 (−14.9, 12.6) N=116 |
0.93 |
| hsIL-6 (pg/mL) | 0.0 (−0.3, 0.2) N=112 |
0.0 (−0.4, 0.1) N=116 |
0.49 | −2.5 (−27.7, 27.3) N=112 |
−2.2 (−30.9, 21.1) N=116 |
0.55 |
| MCP-1 (pg/ml) | −8.5 (−30.8, 18.0) N=110 |
−4.0 (−28.1, 17.5) N=114 |
0.62 | −5.3 (−18.5, 12.8) N=110 |
−2.9 (−17.0, 14.5) N=114 |
0.57 |
| sCD14 (ng/mL) | −37.1 (−425.8, 174.0)** N=112 |
−81.9 (−255.7, 106.8)** N=116 |
0.83 | −1.9 (−22.3, 10.6) N=112 |
−4.1 (−14.0, 8.1) N=116 |
0.90 |
| oxLDL (U/L) | −18.0 (−29.9, −10.8)** N=112 |
−13.4 (−23.6, −5.5) ** N=115 |
0.005 | −25.5 (−34.3, −16.4) N=112 |
−18.6 (−28.8, −8.0) N=115 |
0.001 |
| Lp-PLA2 (ng/mL) | −44.8 (−67.8, −19.8)** N=112 |
−30.2 (−52.7, −10.4)** N=116 |
0.01 | −23.4 (−36.2, −12.5) N=112 |
−17.4 (−29.8, −5.9) N=116 |
0.02 |
| B. Change in Markers of Immune Activation and Arterial Inflammation at Week 52 (mITT population) | ||||||
|---|---|---|---|---|---|---|
| Change in Pitavastatin | Change in Pravastatin | P-value* | Percent Change in Pitavastatin | Percent Change in Pravastatin | P-value* | |
| sCD163 (ng/mL) | 8.6 (−138.5, 122.2) N=98 |
−26.2 (−126.7, 128.6) N=98 |
0.92 | 1.1 (−12.3, 16.5) N=98 |
−2.2 (−13.9, 16.7) N=98 |
0.74 |
| hsIL-6 (pg/mL) | 0.0 (−0.3, 0.4) N=98 |
0.1 (−0.3, 0.4) N=98 |
0.57 | 1.9 (−28.2, 35.3) N=98 |
7.9 (−22.8, 40.9) N=98 |
0.41 |
| MCP-1 (pg/mL) | −2.2 (−31.2, 26.1) N=96 |
−2.2 (−21.7, 26.5) N=95 |
0.95 | −1.3 (−20.6, 21.9) N=96 |
−1.4 (−16.7, 18.5) N=95 |
0.91 |
| sCD14 (ng/mL) | −156.4 (−501.6, 114.5)** N=98 |
10.7 (−294.6, 307.3) N=98 |
0.01 | −10.0 (−23.2, 9.7) N=98 |
0.6 (−15.0, 19.2) N=98 |
0.02 |
| oxLDL (U/L) | −20.5 (−33.4, −8.8)** N=97 |
−13.2 (−25.2, −4.1)** N=95 |
0.02 | −26.9 (−36.0, −10.8) N=97 |
−17.5 (−30.0, −4.5) N=95 |
0.02 |
| Lp-PLA2 (ng/mL) | −44.3 (−77.8, −10.7)** N=97 |
−26.7 (−52.0, −5.0)** N=96 |
0.02 | −26.6 (−35.7, −8.4) N=97 |
−15.5 (−28.1, −3.2) N=96 |
0.005 |
*
P-value for between group difference
**
P<0.05 for within group difference
Abbreviations: sCD163, soluble CD163; hsIL-6, high sensitivity interleukin-6, MCP-1, monocyte chemoattractant protein-1; sCD14, soluble CD14; oxLDL, oxidized low density lipoprotein, Lp-PLA2, lipoprotein-associated phospholipase A2
A. Data are shown for mITT population with biomarker specimens available for Week 12.
B. Data are shown for mITT population with biomarker specimens available for Week 52.